Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103457907> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3103457907 endingPage "594" @default.
- W3103457907 startingPage "591" @default.
- W3103457907 abstract "Tavokinogene Telseplasmid Electroporation Therapy (TAVO) and Pembrolizumab therapy is being studied in subjects with immune checkpoint inhibitor (ICI) resistant melanoma. TAVO is a novel office-based local therapy shown to be effective in patients with advanced melanoma. The technique involves the direct injection of a plasmid encoding IL-12 into an accessible tumor driven by electroporation. The tumor cells have then been shown to express high levels of IL-12 resulting in a local inflammatory response within the tumor microenvironment. The patient with stage IIB, pT3b melanoma was treated with primary tumor resection and found to have a negative sentinel node biopsy. She subsequently developed regional recurrence and was treated with inguinal lymphadenectomy and adjuvant Nivolumab. Despite therapy, she had progression of disease with skin and subcutaneous metastases (in-transit lesions), brain and liver lesions, hilar and iliac nodal disease. She was transitioned to nivolumab + ipilimumab, and Talimogene Laherparepvec (T-VEC) therapy for the in-transit lesions, without success. Stereotactic radiosurgery was used for the brain metastasis. Groin subcutaneous and in-transit lesions were treated with TAVO and intravenous pembrolizumab. Serial physical exams and CT scans were used to assess response. All lesions treated with TAVO resolved. An abscopal response was also noted: hilar and mediastinal lymphadenopathy resolved. The liver mass and pelvic lymphadenopathy decreased in size, and her brain metastasis remained stable after radiation. This case suggests that combination TAVO and Pembrolizumab is a safe and effective local treatment for ICI resistant metastatic melanoma in the setting of rheumatoid arthritis. An abscopal effect was also noted through control of systemic disease." @default.
- W3103457907 created "2020-11-23" @default.
- W3103457907 creator A5020747813 @default.
- W3103457907 creator A5037700231 @default.
- W3103457907 creator A5048797376 @default.
- W3103457907 creator A5073131973 @default.
- W3103457907 creator A5086473468 @default.
- W3103457907 date "2020-01-01" @default.
- W3103457907 modified "2023-10-03" @default.
- W3103457907 title "Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma" @default.
- W3103457907 cites W2025459290 @default.
- W3103457907 cites W2054285572 @default.
- W3103457907 cites W2056537073 @default.
- W3103457907 cites W2067131759 @default.
- W3103457907 cites W2067464172 @default.
- W3103457907 cites W2207779154 @default.
- W3103457907 cites W2469360975 @default.
- W3103457907 cites W2767045610 @default.
- W3103457907 cites W2897748473 @default.
- W3103457907 doi "https://doi.org/10.1016/j.ijscr.2020.11.063" @default.
- W3103457907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7708754" @default.
- W3103457907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33395852" @default.
- W3103457907 hasPublicationYear "2020" @default.
- W3103457907 type Work @default.
- W3103457907 sameAs 3103457907 @default.
- W3103457907 citedByCount "3" @default.
- W3103457907 countsByYear W31034579072021 @default.
- W3103457907 countsByYear W31034579072022 @default.
- W3103457907 crossrefType "journal-article" @default.
- W3103457907 hasAuthorship W3103457907A5020747813 @default.
- W3103457907 hasAuthorship W3103457907A5037700231 @default.
- W3103457907 hasAuthorship W3103457907A5048797376 @default.
- W3103457907 hasAuthorship W3103457907A5073131973 @default.
- W3103457907 hasAuthorship W3103457907A5086473468 @default.
- W3103457907 hasBestOaLocation W31034579071 @default.
- W3103457907 hasConcept C121608353 @default.
- W3103457907 hasConcept C126322002 @default.
- W3103457907 hasConcept C126838900 @default.
- W3103457907 hasConcept C143998085 @default.
- W3103457907 hasConcept C2777658100 @default.
- W3103457907 hasConcept C2777701055 @default.
- W3103457907 hasConcept C2777982462 @default.
- W3103457907 hasConcept C2780030458 @default.
- W3103457907 hasConcept C2780057760 @default.
- W3103457907 hasConcept C2781274730 @default.
- W3103457907 hasConcept C502942594 @default.
- W3103457907 hasConcept C71924100 @default.
- W3103457907 hasConceptScore W3103457907C121608353 @default.
- W3103457907 hasConceptScore W3103457907C126322002 @default.
- W3103457907 hasConceptScore W3103457907C126838900 @default.
- W3103457907 hasConceptScore W3103457907C143998085 @default.
- W3103457907 hasConceptScore W3103457907C2777658100 @default.
- W3103457907 hasConceptScore W3103457907C2777701055 @default.
- W3103457907 hasConceptScore W3103457907C2777982462 @default.
- W3103457907 hasConceptScore W3103457907C2780030458 @default.
- W3103457907 hasConceptScore W3103457907C2780057760 @default.
- W3103457907 hasConceptScore W3103457907C2781274730 @default.
- W3103457907 hasConceptScore W3103457907C502942594 @default.
- W3103457907 hasConceptScore W3103457907C71924100 @default.
- W3103457907 hasLocation W31034579071 @default.
- W3103457907 hasLocation W31034579072 @default.
- W3103457907 hasOpenAccess W3103457907 @default.
- W3103457907 hasPrimaryLocation W31034579071 @default.
- W3103457907 hasRelatedWork W2342781363 @default.
- W3103457907 hasRelatedWork W2607780130 @default.
- W3103457907 hasRelatedWork W2903811712 @default.
- W3103457907 hasRelatedWork W2915045061 @default.
- W3103457907 hasRelatedWork W2981883049 @default.
- W3103457907 hasRelatedWork W2988525911 @default.
- W3103457907 hasRelatedWork W3215044659 @default.
- W3103457907 hasRelatedWork W4283812751 @default.
- W3103457907 hasRelatedWork W4292373623 @default.
- W3103457907 hasRelatedWork W4308181630 @default.
- W3103457907 hasVolume "77" @default.
- W3103457907 isParatext "false" @default.
- W3103457907 isRetracted "false" @default.
- W3103457907 magId "3103457907" @default.
- W3103457907 workType "article" @default.